Skip to main content

Neovaginal Stenosis Management — Stepwise

Neovaginal stenosis is the most clinically significant long-term challenge after feminizing genital surgery. The De Rosa 2024 systematic review (59 studies, 7,338 patients) reports an overall vaginal-stenosis incidence of 5.83% (range 0–34.2%) and a cumulative 9.68% when introital stenosis and contracture are included.[1] Rates reach up to 30% in some series, and stenosis is the most common functional reason for revision vaginoplasty.[2][3] Dilation non-compliance is the single most significant modifiable risk factor.[4]

This is the dedicated management-pathway page. For the host operations, see Penile Inversion Vaginoplasty, Peritoneal Pull-Through Vaginoplasty, and Intestinal Vaginoplasty. For the periurethral / periclitoral architecture that drives introital outcomes, see Feminizing Labiaplasty and Feminizing Urethroplasty.

Definitions and Classification​

A critical limitation is the lack of a standardised definition.[1]

  • Vaginal stenosis (VS): narrowing or shortening of the canal (mid-canal or apical).
  • Introital stenosis (IS): narrowing at the mucocutaneous junction between vulva and canal.
  • Vaginal contracture: complete or near-complete obliteration.
  • Loss of depth: progressive shortening without narrowing.

By location:[5][3][6]

  • Introital (distal) — perineal suture-line scar contracture; most amenable to office-based or minor surgical intervention.
  • Mid-canal — skin-graft contracture, circumferential scarring, granulation tissue.
  • Apical (proximal) — inadequate initial depth, graft necrosis, apex scar contracture.
  • Complete obliteration — total closure; requires major revision.

By severity:[5][7]

  • Mild — responds to increased dilation frequency and/or smaller dilators.
  • Moderate — requires procedural intervention (EUA dilation, scar lysis).
  • Severe / complete — requires major revision vaginoplasty.

Incidence by Surgical Technique​

TechniqueVaginal stenosisIntroital stenosisNotes
Penile inversion vaginoplasty (PIV) — overall5.70%3.13%De Rosa SR — most data[1]
PIV with skin-graft augmentation1.2–12%—Neovaginal necrosis 0–22.8%[8]
PIV with scrotal flap0–6.3%—Limited data[8]
Primary intestinal vaginoplasty0.20%4.7%Self-lubricating mucosa[1]
Peritoneal-flap vaginoplastyLow (limited data)—Emerging technique[2]
PIV (OHSU, n = 200)4.0%1.5%Single high-volume surgeon[3]
PIV (Levy n = 240)2.1% requiring reoperation—Short follow-up[4]

The notably low canal-stenosis rate in intestinal vaginoplasty (0.20%) vs PIV (5.70%) reflects the inherent contracture-resistance of bowel mucosa. Introital-stenosis rates are similar (PIV 3.13% vs intestinal 4.7%), confirming that the mucocutaneous suture line drives introital outcomes regardless of canal-lining tissue.[1]

Risk Factors​

Dilation non-compliance — the dominant risk factor​

Non-compliance is the only factor consistently and independently associated with stenosis and reoperation:[4][9]

  • Levy 2019 (n = 240) — non-compliance with dilation and activity restrictions was the only factor significantly associated with increased complications or reoperation on multivariate analysis.[4]
  • Permanent stenosis is framed as a direct complication of not dilating.[9]
  • The AAFP recommends increasing dilation frequency, with pelvic-floor PT, as first-line treatment.[9]

Predictors of dilation difficulty (Shamamian 2025, n = 614)[10]​

Independent predictors on multivariate analysis:

  • Unemployment — OR 2.740 (95% CI 1.587–4.732, p < .001)
  • HIV — OR 2.59 (1.02–6.55, p = 0.046)
  • Psychiatric comorbidity besides gender dysphoria — OR 1.61 (1.06–2.45, p = 0.025)
  • Primary peritoneal graft — OR 3.202 (1.212–8.460, p = 0.019)

Surgical / patient factors​

  • Skin-graft use — neovaginal stenosis 1.2–12% when grafts augment PIV; precursor neovaginal necrosis 0–22.8%.[8]
  • Granulation tissue — significant predictor of revision (p = 0.006).[11]
  • Wound dehiscence / infection — disrupts neovaginal lining and drives scar contracture.
  • Insufficient initial depth — inadequate canal dissection or donor tissue.
  • BMI > 24.9, diabetes, smoking, cardiovascular disease — flagged as significant in the 2025 International Delphi Consensus.[12]
  • Age, BMI, HRT duration — not independently associated with complications in Gaither 2018 (n = 330).[13]
  • History of abuse — significantly higher preoperative pelvic-floor dysfunction (91% vs 31%, p < 0.001).[14]

Prevention — Dilation Protocols​

Standard schedule​

The 2025 International Delphi Consensus recommends 3 daily 30-min sessions postoperatively.[12] ACOG 2021 affirms successful recovery requires patient commitment to a regimen of up to 3× per day.[15]

IntervalFrequency
Weeks 1–4 (after packing / stent removal)3× daily, 15–30 min
Months 2–32–3× daily
Months 3–61–2× daily
Months 6–121× daily
> 12 monthsLifelong maintenance — several times per week, or as needed if regular vaginal intercourse

Anchors: AAFP[9], ACOG[15], Delphi[12].

Dilator sizing​

Begin smaller; gradually increase. For struggling patients, ACOG advises increasing lubricant and downsizing dilators to enable more frequent / deeper dilation, then re-escalating size.[15] A standardised 13 cm dilator set is commonly used.[16]

The patient-reported dilation experience (Gomez 2026 prospective longitudinal, the first of its kind)[16]​

  • Mean dilation: 6.6 ± 1.4 days/week, 2.4 ± 0.9 times/day.
  • Session duration: 38.3 ± 16 min.
  • Mean depth achieved: 4.05 ± 1.32 on a standardised 13 cm dilator set — no significant decline over time.
  • 100% of patients reported at least one dilation difficulty.
  • Most common challenges: tightness 71%, bleeding 71%, pain 65%, discharge 47%, logistical barriers 24%.
  • Challenges declined significantly after 6 months (p < 0.05).

Pelvic-floor physical therapy (PFPT)​

Jiang / OHSU program (n = 77):[14]

  • 94% attended PFPT at least once.
  • Preoperative screening identified 42% with pelvic-floor dysfunction and 37% with bowel dysfunction.
  • Resolution at first postoperative visit: 69% pelvic-floor / 73% bowel.
  • Pre- + postoperative PFPT vs postoperative-only: significantly lower postoperative pelvic-floor dysfunction (28% vs 86%, p = 0.006).
  • Successful dilation at 3 months: 89%.

FLOWER Trial — RCT, n = 41 (the only RCT in this space):[17]

  • Randomised to PFPT at 3 and 6 wk postoperatively vs no PFPT.
  • At 12 wk: median vaginal length 12.5 cm, ease of dilation 7.3/10, pain with dilation 2.4/10.
  • No significant differences in length, ease, pain, or pelvic-floor symptoms between groups.
  • Implication: routine postoperative PFPT may not improve outcomes for all comers; benefit likely concentrated in subgroups (preoperative pelvic-floor dysfunction, history of abuse).

Manrique 2019 (n = 40):[18]

  • High preoperative pelvic-floor dysfunction.
  • PFPT significantly reduced symptom severity (p < 0.05).

The Jiang–FLOWER tension argues that PFPT should be selectively applied to patients with preoperative pelvic-floor dysfunction rather than universally prescribed.[14][17][18]

Stepwise Management Algorithm​

Step 1 — Conservative (first-line)​

For mild stenosis or early loss of depth / caliber:[9][15]

  • Increase dilation frequency — the single most important intervention.
  • Downsize dilator — smaller dilator, gradual re-escalation.
  • Generous lubricant — water- or silicone-based.
  • Pelvic-floor PT referral — especially for pain, tightness, difficulty relaxing.
  • Treat contributing factors — granulation tissue (see below), infection, hair regrowth.
  • Persistent pain or dilation difficulty → refer to surgeon.[9]

Step 2 — Office-based procedures​

For moderate stenosis not responding to conservative measures:

  • Dilation under anaesthesia (EUA) — examination + serial dilation; may be combined with scar lysis.
  • Scar lysis / incision — sharp or electrocautery incision of circumferential scar bands.
  • Granulation treatment — silver nitrate cautery ± betamethasone suppositories (see Granulation section).
  • Introital revision — local tissue rearrangement, Z-plasty, or V-flap advancement for isolated introital stenosis.

Step 3 — Surgical revision for moderate stenosis​

For moderate stenosis with preserved canal space but inadequate dimensions:

  • Full-thickness skin-graft (FTSG) revision vaginoplasty (van der Sluis 2016 comparative):[19]
    • Perineal approach; OR 131 ± 35 min.
    • Successful reconstruction in 81% (26/32).
    • Mean neovaginal depth 12.5 ± 2.8 cm.
    • Rectal perforation 19% — higher than intestinal approach.
    • Donor sites: groin, inner thigh, lower abdomen.
  • Robotic peritoneal-flap revision vaginoplasty (Dy 2021 NYU; Celis 2026 step-by-step):[20][3]
    • n = 24; all had prior PIV; revision at median 35.3 months after primary.
    • Flaps from posterior bladder and pararectal fossa, advanced to stenosed-cavity edges.
    • Depth 13.6 cm (range 10.9–14.5); width 3.6 cm.
    • No intraoperative complications from peritoneal-flap harvest; no rectal injuries.
    • 1 return-to-OR for canal bleeding.
    • OR time 5 h initially → 3 h in the Celis step-by-step technique paper.
    • Discharge within first week; serial vaginoscopies for healing assessment.[3]

Step 4 — Severe stenosis / complete obliteration​

  • Laparoscopic intestinal (sigmoid) revision vaginoplasty (van der Sluis 2016):[19]
    • Successful reconstruction in 91% (19/21).
    • Mean depth 15.9 ± 1.4 cm — significantly deeper than FTSG (p < 0.05).
    • OR 191 ± 45 min; rectal perforation 10%.
  • Biological-graft (UBM, urinary bladder matrix) reconstruction — Gupta 2019 case report:[21]
    • Novel approach for recurrent introital stenosis with granulation tissue.
    • UBM acts as scaffold for smooth-muscle and matrix regeneration.
    • Successful reconstruction of neovaginal introitus after failed prior revisions.
    • Improvement in comfort, hygiene, and QoL.

Comparison of Revision Techniques​

TechniqueSuccessDepthOR timeRectal perforationKey advantageKey disadvantage
FTSG revision81%12.5 ± 2.8 cm131 ± 35 min19%Shorter OR; perinealLess depth; higher rectal-injury rate; requires dilation[19]
Laparoscopic intestinal revision91%15.9 ± 1.4 cm191 ± 45 min10%Greater depth; self-lubricatingLonger OR; bowel anastomosis; mucorrhea[19]
Robotic peritoneal-flap revision100% (24/24 Dy 2021)13.6 cm180–300 min0%No rectal injury; no bowel anastomosis; minimal donor-site morbidityRobotic platform; limited long-term data[20][3]
Biological graft (UBM)Case report———Scaffold for recurrent introital stenosisSingle case[21]

Granulation Tissue — Key Precursor to Stenosis​

Granulation tissue (hypergranulation) is among the most common minor postoperative findings and is a significant precursor to stenosis if untreated — and a significant predictor of requiring revision (p = 0.006).[9][11][13]

Incidence. Gaither 2018 (n = 330) — common complication at median 4.4 mo postoperatively.[13]

Management:[9][22]

  • Silver nitrate cautery — first-line; via speculum; often repeated.
  • Betamethasone suppositories + silver nitrate — Gharavi 2026 matched cohort (16 per arm): adding betamethasone significantly improved resolution (p = 0.035 after excluding cases requiring anaesthetic cautery). Moderate / severe hypergranulation resolved more often in the betamethasone group (86% / 50%) than silver-nitrate-alone (60% / 25%), with fewer median treatments (2 vs 3.5 moderate; 4 vs 5 severe).[22]
  • Cauterisation under anaesthesia — severe / refractory.
  • Routine monitoring — yearly or biennial pelvic exam.[9]

Introital Stenosis — Specific Considerations​

Introital stenosis occurs at a similar rate across PIV (3.13%) and intestinal vaginoplasty (4.7%) — confirming that the introital suture line, common to all techniques, is the primary driver.[1]

Pathophysiology: circumferential scarring at the mucocutaneous junction; granulation tissue at the introitus (particularly common after intestinal vaginoplasty[21]); suture-line tension; inadequate primary introital caliber.

Management:

  • Conservative — increased dilation focused on introital caliber.
  • Office-based — scar lysis, Z-plasty, V-flap meatoplasty.
  • Surgical — local tissue rearrangement, posterior web release, biological graft (UBM) for recurrent cases.[21]
  • The Raigosa refinement (n = 167) demonstrates that incorporating labia-minora + clitoral-hood creation significantly reduces introital complications — meatal stenosis 15.5% → 1.5% (p = 0.003), hemorrhage 31% → 12.5% (p = 0.006), aesthetic revision 20.3% → 4.6% (p = 0.004); see the Feminizing Labiaplasty page for the full dataset.[23]

Special Populations​

Peritoneal-flap vaginoplasty patients — 3.2× higher odds of dilation difficulty vs PIV (Shamamian OR 3.20, 95% CI 1.21–8.46, p = 0.019). Peritoneum may be more prone to contracture and requires more rigorous dilation adherence.[10]

Intestinal vaginoplasty patients — canal stenosis is very rare (0.20%), but the technique carries unique complications that contribute to revision (Robinson 2023 SR):[24]

  • Stenosis was the most common complication (11% of 654 vaginoplasties).
  • Mucorrhea 7%, prolapse 6%, malodor 5%.
  • Diversion colitis can present as neovaginal bleeding years later.
  • Average return-to-OR rate 18%; 6 segments developed vascular compromise; 2 reported mortalities.

Adolescents / post-puberty-suppression cohorts — limited donor tissue may necessitate alternative canal lining for the primary procedure, with downstream stenosis-risk implications. The Delphi consensus emphasises individualised, comorbidity-based assessment.[12]

Long-Term Surveillance​

AAFP and ACOG recommendations:[9][15]

  • Lifelong dilation — permanent stenosis is the complication of not dilating.
  • Pelvic examinations yearly or every other year for stenosis, granulation tissue, hair regrowth.
  • Canal should accommodate a Pederson speculum; an anoscope is a more slender alternative for narrower canals.
  • New vaginal symptoms → pelvic examination.
  • Persistent pain or dilation difficulty → surgical referral.
  • For peritoneum- or colon-lined neovaginas, vaginal bleeding should prompt biopsy to evaluate for bowel pathology (adenocarcinoma, IBD) — see the Intestinal Vaginoplasty page neoplasia and diversion-colitis subsections.[9]

Evidence Limitations​

  • No standardised definition of vaginal stenosis — studies variably use symptoms, exam findings, dilator size, or need for intervention; cross-study comparisons unreliable.[1]
  • No validated grading system for severity.
  • No comparative trials between revision techniques (FTSG vs intestinal vs peritoneal flap).
  • No standardised dilation protocols — schedules are expert opinion, not comparative evidence.
  • Long-term outcomes of revision beyond 3–5 yr poorly characterised.
  • The FLOWER RCT is the only randomised trial evaluating PFPT — found no benefit for routine postoperative PFPT, conflicting with observational data.[17]
  • PROMs are underrepresented — Gomez 2026 is the first prospective longitudinal assessment of the dilation experience.[16]
  • The 2025 International Delphi Consensus represents the first expert consensus on perioperative management but acknowledges unresolved issues.[12]

References​

1. De Rosa P, Kent M, Regan M, Purohit RS. Vaginal stenosis after gender-affirming vaginoplasty: a systematic review. Urology. 2024;186:69–74. doi:10.1016/j.urology.2024.02.005

2. Motiwala ZY, Misra S, Desai A, et al. Postoperative urogynecologic complications after gender-affirming surgery: a narrative review. Int Urogynecol J. 2026;37(4):805–822. doi:10.1007/s00192-025-06405-6

3. Celis V, Rodríguez VI, Fumero LK, et al. Robotic peritoneal flap revision vaginoplasty: step-by-step technique: tips & tricks. Int Urogynecol J. 2026. doi:10.1007/s00192-026-06617-4

4. Levy JA, Edwards DC, Cutruzzula-Dreher P, et al. Male-to-female gender reassignment surgery: an institutional analysis of outcomes, short-term complications, and risk factors for 240 patients undergoing penile-inversion vaginoplasty. Urology. 2019;131:228–233. doi:10.1016/j.urology.2019.03.043

5. Dietrich JE. Review of surgical neovagina techniques and management of vaginal stricture. J Pediatr Adolesc Gynecol. 2022;35(2):121–126. doi:10.1016/j.jpag.2021.10.001

6. Ferrando CA. Vaginoplasty complications. Clin Plast Surg. 2018;45(3):361–368. doi:10.1016/j.cps.2018.03.007

7. Shoureshi P, Dy GW, Dugi D. Neovaginal canal dissection in gender-affirming vaginoplasty. J Urol. 2021;205(4):1110–1118. doi:10.1097/JU.0000000000001516

8. Salibian AA, Schechter LS, Kuzon WM, et al. Vaginal canal reconstruction in penile inversion vaginoplasty with flaps, peritoneum, or skin grafts: where is the evidence? Plast Reconstr Surg. 2021;147(4):634e–643e. doi:10.1097/PRS.0000000000007779

9. Jackson Q, Yedlinsky NT, Gray M. Lifelong care of patients after gender-affirming surgery. Am Fam Physician. 2024;109(6):560–565.

10. Shamamian PE, Chen D, Wang A, et al. Predictors of dilation difficulty in gender-affirming vaginoplasty. J Plast Reconstr Aesthet Surg. 2025;101:178–186. doi:10.1016/j.bjps.2024.11.042

11. Boas SR, Ascha M, Morrison SD, et al. Outcomes and predictors of revision labiaplasty and clitoroplasty after gender-affirming genital surgery. Plast Reconstr Surg. 2019;144(6):1451–1461. doi:10.1097/PRS.0000000000006282

12. Pezzoli M, Lo Re M, Pizziconi V, et al. International Delphi consensus on feminising genital surgery in assigned-male-at-birth individuals. BJU Int. 2026. doi:10.1111/bju.70196

13. Gaither TW, Awad MA, Osterberg EC, et al. Postoperative complications following primary penile inversion vaginoplasty among 330 male-to-female transgender patients. J Urol. 2018;199(3):760–765. doi:10.1016/j.juro.2017.10.013

14. Jiang DD, Gallagher S, Burchill L, Berli J, Dugi D. Implementation of a pelvic floor physical therapy program for transgender women undergoing gender-affirming vaginoplasty. Obstet Gynecol. 2019;133(5):1003–1011. doi:10.1097/AOG.0000000000003236

15. Committee on Gynecologic Practice and Committee on Health Care for Underserved Women. Health care for transgender and gender diverse individuals: ACOG Committee Opinion, Number 823. Obstet Gynecol. 2021;137(3):e75–e88. doi:10.1097/AOG.0000000000004294

16. Gomez DA, Ley M, Hu AC, et al. Longitudinal patient-reported outcomes of vaginal dilation after penile inversion vaginoplasty. J Sex Med. 2026;23(4):qdag068. doi:10.1093/jsxmed/qdag068

17. Ferrando CA, Mishra K, Grimstad FW, Weigand NW, Pikula C. A randomized trial comparing perioperative pelvic floor physical therapy to current standard of care in transgender women undergoing vaginoplasty for gender affirmation: the FLOWER trial. Int Urogynecol J. 2023;34(12):2985–2993. doi:10.1007/s00192-023-05623-0

18. Manrique OJ, Adabi K, Huang TC, et al. Assessment of pelvic floor anatomy for male-to-female vaginoplasty and the role of physical therapy on functional and patient-reported outcomes. Ann Plast Surg. 2019;82(6):661–666. doi:10.1097/SAP.0000000000001680

19. van der Sluis WB, Bouman MB, Buncamper ME, Mullender MG, Meijerink WJ. Revision vaginoplasty: a comparison of surgical outcomes of laparoscopic intestinal versus perineal full-thickness skin graft vaginoplasty. Plast Reconstr Surg. 2016;138(4):793–800. doi:10.1097/PRS.0000000000002598

20. Dy GW, Blasdel G, Shakir NA, Bluebond-Langner R, Zhao LC. Robotic peritoneal flap revision of gender-affirming vaginoplasty: a novel technique for treating neovaginal stenosis. Urology. 2021;154:308–314. doi:10.1016/j.urology.2021.03.024

21. Gupta A, Francis S, Stewart R, Hobson D, Meriwether KV. Repair of colonic neovaginal stenosis using a biological graft in a male-to-female transgender patient. Int Urogynecol J. 2019;30(4):661–663. doi:10.1007/s00192-018-3800-6

22. Gharavi A, Sanchez Figueroa N, Lin A, Fahradyan V, Martinez-Jorge J. The addition of betamethasone suppositories to silver nitrate treatment for hypergranulation tissue following penile inversion vaginoplasty: a matched cohort study. Ann Plast Surg. 2026;96(1):79–82. doi:10.1097/SAP.0000000000004542

23. Raigosa M, Avvedimento S, Descarrega J, et al. Refinement procedures for clitorolabiaplasty in male-to-female gender-affirmation surgery: more than an aesthetic procedure. J Sex Med. 2020;17(12):2508–2517. doi:10.1016/j.jsxm.2020.08.006

24. Robinson IS, Cripps CN, Bluebond-Langner R, Zhao LC. Operative management of complications following intestinal vaginoplasty: a case series and systematic review. Urology. 2023;180:105–112. doi:10.1016/j.urology.2023.07.005